Identifying B7-H3 and LAG3 as surface molecules expressed on CD4 CTLs with enhanced cytotoxic potential may provide new opportunities for manipulating CD4+ T cells in T cell therapies for B-ALL and other HLA class II-expressing tumors. The gene discussed is LAG3; the disease is precursor B-cell acute lymphoblastic leukemia.